J Dig Cancer Res.
2023 Dec;11(3):147-156. 10.52927/jdcr.2023.11.3.147.
Updates of Chemotherapy for Pancreatic Cancer
- Affiliations
-
- 1Department of Gastroenterology, CHA Bundang Medical Center, CHA University, Seongnam, Korea
- KMID: 2549666
- DOI: http://doi.org/10.52927/jdcr.2023.11.3.147
Abstract
- Pancreatic cancer is one of the most aggressive cancers, and it is expected to become the second-leading cause of cancer-related death in the United States by 2030. Its 5-year survival rate is <10% and approximately 15% of cases are eligible for surgical treatment during diagnosis. Furthermore, the risk of recurrence within 1 year postoperative is as high as 50%. Therefore, chemotherapy plays a crucial role in pancreatic cancer treatment. Survival rates are speculated to have improved since the introduction of FOLFIRINOX and gemcitabine/nab-paclitaxel combination therapy for metastatic pancreatic cancer in the 2010s. Additionally, the implementation of both neoadjuvant and adjuvant treatments in resectable and borderline resectable pancreatic cancer caused better outcomes compared to upfront surgery. Recently, not only have these medications advanced in development, but so have PARP inhibitors and KRAS inhibitors, contributing to the treatment landscape. This study aimed to explore the latest insights into chemotherapy for pancreatic cancer.
